Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sinorda and Porton Partner to Advance Cell and Gene Therapy Products

publication date: Apr 25, 2022

Guizhou Sinorda Biomedicine, a novel cell and gene therapy company, announced a long-term strategic cell and gene therapy R&D partnership with CDMO Suzhou Porton Advanced Solutions. Sinorda is developing innovative digestive tract, immunotherapy and oncolytic virus products, with several candidates in clinical stage. Porton will provide services to accelerate the development of Sinorda’s cell therapies, including its Sentinel lymph node T cell immunotherapy for colorectal cancer. Porton offers an end-to-end gene and cell therapy CDMO service platform for plasmids, cell therapy, gene therapy, oncolytic virus, mRNA therapy and Bacterial Therapy. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital